Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer

Yun Jung Choi, Byoung Chul Cho, Yong Hyu Jeong, Hyo Jung Seo, Hyun Jeong Kim, Arthur Cho, Jae Hoon Lee, Mijin Yun, Tae Joo Jeon, Jong Doo Lee, Won Jun Kang

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications. Methods: A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status. Results: EGFR mutations were found in 57 patients (60. 8 %). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11. 1 ± 5. 7 vs. 9. 8 ± 4. 4, P = 0. 103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P = 0. 003 and 0. 009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P = 0. 004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors. Conclusion: In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalNuclear Medicine and Molecular Imaging
Volume46
Issue number3
DOIs
Publication statusPublished - 2012 Sep 1

Fingerprint

Fluorodeoxyglucose F18
Epidermal Growth Factor Receptor
Lung Neoplasms
Mutation
Exons
Survival
Non-Small Cell Lung Carcinoma
erbB-1 Genes
Neoplasms
Positron-Emission Tomography
Disease-Free Survival
Liver

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

Choi, Yun Jung ; Cho, Byoung Chul ; Jeong, Yong Hyu ; Seo, Hyo Jung ; Kim, Hyun Jeong ; Cho, Arthur ; Lee, Jae Hoon ; Yun, Mijin ; Jeon, Tae Joo ; Lee, Jong Doo ; Kang, Won Jun. / Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. In: Nuclear Medicine and Molecular Imaging. 2012 ; Vol. 46, No. 3. pp. 169-175.
@article{f0b3adb36784406e99bbb8a16a067056,
title = "Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer",
abstract = "Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications. Methods: A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status. Results: EGFR mutations were found in 57 patients (60. 8 {\%}). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11. 1 ± 5. 7 vs. 9. 8 ± 4. 4, P = 0. 103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P = 0. 003 and 0. 009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P = 0. 004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors. Conclusion: In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.",
author = "Choi, {Yun Jung} and Cho, {Byoung Chul} and Jeong, {Yong Hyu} and Seo, {Hyo Jung} and Kim, {Hyun Jeong} and Arthur Cho and Lee, {Jae Hoon} and Mijin Yun and Jeon, {Tae Joo} and Lee, {Jong Doo} and Kang, {Won Jun}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s13139-012-0142-z",
language = "English",
volume = "46",
pages = "169--175",
journal = "Nuclear Medicine and Molecular Imaging",
issn = "1869-3474",
publisher = "Springer Verlag",
number = "3",

}

Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer. / Choi, Yun Jung; Cho, Byoung Chul; Jeong, Yong Hyu; Seo, Hyo Jung; Kim, Hyun Jeong; Cho, Arthur; Lee, Jae Hoon; Yun, Mijin; Jeon, Tae Joo; Lee, Jong Doo; Kang, Won Jun.

In: Nuclear Medicine and Molecular Imaging, Vol. 46, No. 3, 01.09.2012, p. 169-175.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer

AU - Choi, Yun Jung

AU - Cho, Byoung Chul

AU - Jeong, Yong Hyu

AU - Seo, Hyo Jung

AU - Kim, Hyun Jeong

AU - Cho, Arthur

AU - Lee, Jae Hoon

AU - Yun, Mijin

AU - Jeon, Tae Joo

AU - Lee, Jong Doo

AU - Kang, Won Jun

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications. Methods: A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status. Results: EGFR mutations were found in 57 patients (60. 8 %). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11. 1 ± 5. 7 vs. 9. 8 ± 4. 4, P = 0. 103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P = 0. 003 and 0. 009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P = 0. 004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors. Conclusion: In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.

AB - Purpose: Mutations in the epidermal growth factor receptor (EGFR) gene have been identified as potential targets for the treatment and prognostic factors for non-small cell lung cancer (NSCLC). We assessed the correlation between fluorodeoxyglucose (FDG) uptake and EGFR mutations, as well as their prognostic implications. Methods: A total of 163 patients with pathologically confirmed NSCLC were enrolled (99 males and 64 females; median age, 60 years). All patients underwent FDG positron emission tomography before treatment, and genetic studies of EGFR mutations were performed. The maximum standardized uptake value (SUVmax) of the primary lung cancer was measured and normalized with regard to liver uptake. The SUVmax between the wild-type and EGFR mutant groups was compared. Survival was evaluated according to SUVmax and EGFR mutation status. Results: EGFR mutations were found in 57 patients (60. 8 %). The SUVmax tended to be higher in wild-type than mutant tumors, but was not significantly different (11. 1 ± 5. 7 vs. 9. 8 ± 4. 4, P = 0. 103). The SUVmax was significantly lower in patients with an exon 19 mutation than in those with either an exon 21 mutation or wild type (P = 0. 003 and 0. 009, respectively). The EGFR mutation showed prolonged overall survival (OS) compared to wild-type tumors (P = 0. 004). There was no significant difference in survival according to SUVmax. Both OS and progression-free survival of patients with a mutation in exon 19 were significant longer than in patients with wild-type tumors. Conclusion: In patients with NSCLC, a mutation in exon 19 was associated with a lower SUVmax and is a reliable predictor for good survival.

UR - http://www.scopus.com/inward/record.url?scp=84865745654&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865745654&partnerID=8YFLogxK

U2 - 10.1007/s13139-012-0142-z

DO - 10.1007/s13139-012-0142-z

M3 - Article

AN - SCOPUS:84865745654

VL - 46

SP - 169

EP - 175

JO - Nuclear Medicine and Molecular Imaging

JF - Nuclear Medicine and Molecular Imaging

SN - 1869-3474

IS - 3

ER -